Compounded Semaglutide in Houston: What Patients Need to Know
Compounded semaglutide is widely available across Houston-area clinics, but the rules-and the risks-are changing fast. Here's what every patient needs to know before starting.
Reviewed for accuracy against current FDA guidance, peer-reviewed clinical trial data (STEP, SURMOUNT trials), and manufacturer prescribing information. See our editorial standards.
Compounded semaglutide costs $150–$400/month at most Houston clinics — a fraction of what brand-name Wegovy or Ozempic runs without insurance. It became widely available when the FDA declared a semaglutide shortage, allowing state-licensed compounding pharmacies to legally produce their own versions, but that regulatory window is closing. Patients across Houston and its suburbs — Katy, The Woodlands, Pearland, Cypress — are now asking whether compounded semaglutide is still a safe, legal option and whether their clinic is operating above board. This article covers how compounded semaglutide differs from the brand-name drugs, where Texas law currently stands, what to expect on cost, and the questions worth asking any physician-supervised weight loss clinic before you start treatment.
1What Is Compounded Semaglutide - and How Does It Differ from Wegovy® or Ozempic®?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk. FDA-approved brand-name versions include Ozempic® (2 mg/dose, indicated for type 2 diabetes), Wegovy® (2.4 mg/week, indicated for chronic weight management), and Rybelsus® (oral tablet). Compounded semaglutide, by contrast, is mixed by a licensed compounding pharmacy - typically as a multi-dose vial for subcutaneous self-injection - using the active pharmaceutical ingredient (API) or, in some formulations, a semaglutide salt such as semaglutide acetate or semaglutide sodium. This is a critical distinction: the FDA has never approved any semaglutide salt for human use, and the agency issued guidance in 2024 stating that semaglutide salts are not the same as the base ingredient used in Wegovy® and Ozempic®. Compounded drugs are not FDA-approved, meaning they do not go through the same pre-market review for safety, efficacy, or manufacturing consistency. That doesn't make every compounded product dangerous, but it does mean patients and physicians bear more responsibility for vetting the source.
2The FDA Shortage Story: Why Compounded Semaglutide Became So Common in Houston
From 2022 through much of 2024, Wegovy® and Ozempic® appeared on the FDA's drug shortage list - a designation that legally permitted state-licensed and 503A/503B compounding pharmacies to prepare copies of the drug for individual patients. Houston's sprawling medical corridor, combined with a high density of direct-pay weight loss clinics in suburbs like Sugar Land and Cypress, made the market fertile. Dozens of medspa and telehealth operators launched compounded semaglutide programs, often advertising prices of $150–$250 per month compared to Wegovy®'s retail sticker price north of $1,300. The FDA removed semaglutide from the shortage list in early 2025, which triggered a legal deadline for most 503A pharmacies to stop producing copies and for 503B outsourcing facilities to wind down large-scale compounding. If a Houston clinic is still offering compounded semaglutide after that deadline, it should be operating under a specific, documented medical rationale - such as a patient allergy to an inactive ingredient or a required dose strength not commercially available - rather than simply offering a cheaper substitute.
3What the Clinical Trial Data Actually Shows (STEP Trials)
The efficacy data for semaglutide in weight management comes from the brand-name product studied in the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity who received 2.4 mg subcutaneous semaglutide once weekly for 68 weeks achieved a mean body weight reduction of 14.9%, compared with 2.4% in the placebo group. STEP 3 demonstrated up to 16% mean weight loss when semaglutide was combined with intensive behavioral intervention. STEP 4 showed that discontinuing semaglutide led to substantial weight regain within one year, underscoring that this is a long-term treatment, not a short course. It is essential to understand that these results were established for the FDA-approved formulation of semaglutide at specific dose escalation schedules. No large-scale, peer-reviewed randomized controlled trial has established equivalent efficacy or safety for compounded semaglutide formulations, semaglutide salts, or add-on additives (such as B12 or L-carnitine) sometimes mixed into compounded vials.
4Texas Law, Compounding Pharmacies, and What 'Licensed' Really Means
Texas patients have a right to know exactly who is making their medication. In Texas, compounding pharmacies are regulated by the Texas State Board of Pharmacy (TSBP) and must hold either a Class A (traditional) or Class C (sterile preparations) pharmacy license. Sterile injectable compounded semaglutide must come from a Class C-licensed facility. Larger 503B outsourcing facilities are regulated by the FDA under the Drug Quality and Security Act of 2013 and are subject to current Good Manufacturing Practice (cGMP) standards - a higher bar than 503A pharmacies. When evaluating a Houston-area weight loss clinic, ask: Is the compounding pharmacy Texas-licensed? Is it 503A or 503B? Can the clinic provide a Certificate of Analysis (CoA) from a third-party lab confirming potency, sterility, and the absence of contaminants for the specific batch you'll receive? Reputable physician-supervised clinics in areas like The Woodlands and Pearland should readily provide this documentation. If a clinic hesitates or cannot name its pharmacy partner, that is a meaningful red flag.
5Cost Reality Check: Compounded vs. Brand-Name Semaglutide in the Houston Area
Cost remains the single biggest driver of interest in compounded semaglutide across Houston. Here is a realistic local cost snapshot as of mid-2026. Brand-name Wegovy® without insurance runs approximately $1,350–$1,450 per month at Houston-area pharmacies (H-E-B, CVS, Walgreens). Novo Nordisk's savings card can reduce this to $0–$225/month for commercially insured patients who qualify, though prior authorization requirements are common. Compounded semaglutide programs at local direct-pay clinics have typically ranged from $150–$350/month, inclusive of medication, supplies, and often a monthly telehealth check-in. On the insurance front, major Texas carriers - including Blue Cross Blue Shield of Texas, Aetna, UnitedHealthcare, and Cigna - have highly variable formulary coverage for Wegovy®. As of 2026, Texas Medicaid (STAR/CHIP) does not cover Wegovy® for weight loss alone. Patients with a formal diagnosis of type 2 diabetes have a clearer path to Ozempic® coverage. Always verify your specific plan's prior authorization criteria and step-therapy requirements before assuming you need to go the compounded route for cost reasons.
6Safety Considerations: What Houston Patients Have Reported - and What the FDA Has Flagged
The FDA has issued multiple safety communications relevant to compounded semaglutide. In October 2024, the agency warned consumers about medications labeled as semaglutide that were found to contain semaglutide sodium or semaglutide acetate - untested salt forms - rather than the base ingredient used in approved products. Separately, the FDA received adverse event reports involving incorrect dosing from compounded multi-dose vials, including cases of nausea, vomiting, and hypoglycemia requiring emergency care. The STEP trials documented that the most common adverse effects of brand-name semaglutide were gastrointestinal - nausea (44%), diarrhea (30%), vomiting (24%) - and were generally manageable with the protocol's slow dose-escalation schedule. Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical (based on rodent data) concern about medullary thyroid carcinoma. Any Houston clinic prescribing semaglutide - compounded or branded - should take a thorough personal and family history, including thyroid cancer history, and should not prescribe to patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
7How to Evaluate a Houston-Area Weight Loss Clinic Offering Compounded Semaglutide
Greater Houston's sheer geographic size means you have genuine choices across dozens of physician-supervised clinics in neighborhoods from Midtown to Katy to Pearland. When comparing programs, ask the following questions before you commit: (1) Is a licensed physician - not just a nurse practitioner or PA - reviewing your medical history before prescribing? (2) Does the clinic obtain baseline labs (metabolic panel, HbA1c, thyroid function, lipid panel)? (3) Can the clinic clearly identify the compounding pharmacy by name and provide its TSBP license number and a batch-specific Certificate of Analysis? (4) What is the clinic's documented medical justification for prescribing compounded rather than brand-name semaglutide now that the FDA shortage designation has ended? (5) Is there a clear protocol for managing side effects, including 24/7 or after-hours provider access? (6) Does the program include behavioral and nutritional support, or is it medication-only? STEP trial participants who received intensive lifestyle counseling alongside semaglutide achieved the strongest and most durable outcomes. A medication-only approach may produce results, but it leaves significant efficacy on the table.
8The Path Forward: Transitioning to Brand-Name Medication and Long-Term Weight Management
For Houston patients currently on compounded semaglutide who are concerned about the changing regulatory environment, a conversation with your prescribing physician is the right first step - not an abrupt stop. Discontinuing semaglutide suddenly carries real risks: the STEP 4 trial demonstrated that patients who discontinued after 20 weeks of dose escalation regained approximately two-thirds of their lost weight within 52 weeks. If you're seeing results and want to continue, explore whether brand-name Wegovy® or Ozempic® is now accessible to you through insurance, the Novo Nordisk patient assistance program (NovoCare®), or Mark Cuban's Cost Plus Drugs platform, which has expanded its formulary. Patients with a BMI ≥30, or ≥27 with a qualifying comorbidity such as hypertension, dyslipidemia, or sleep apnea, have the strongest case for commercial insurance coverage with a properly documented prior authorization. Physician-supervised clinics in Sugar Land, The Woodlands, and Cypress that are committed to long-term patient care - rather than transactional prescription writing - will help you understand this transition proactively.
Compounded semaglutide has given thousands of Houston-area patients an entry point into evidence-based GLP-1 therapy that brand-name pricing made inaccessible. But the regulatory goalposts have moved, and the difference between a safe program and a risky one comes down to your clinic's transparency, physician oversight, and pharmacy sourcing. Use the Houston Weight Loss Directory to find physician-supervised clinics near you - in Katy, Sugar Land, The Woodlands, Pearland, and Cypress - that can answer every question in this guide confidently.
Sources & References
Clinical data referenced in this article is drawn from the FDA drug database, peer-reviewed publications (STEP trials, SURMOUNT trials), and manufacturer prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro. Pricing figures reflect publicly available estimates and may vary. Insurance coverage information is general guidance — confirm your specific benefits with your plan.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any weight loss medication or program.